Learning Objectives
- Understand the burden of renal disease in patients with diabetes.
- Discuss the renal subgroup data from the EMPA-REG OUTCOMES trial.
- Understand the mechanisms of cardio-renal protection with Empagliflozin.
- Provide clinicians with practical advice about how to incorporate these data in to the management algorithm for individuals with diabetes.
Faculty
Lawrence A. Leiter
MD, FRCPC, FACP, FACE, FAHA
Endocrinologist, St. Michael’s Hospital
Professor of Medicine and Nutritional Sciences, University of Toronto
Christopher T. Chan
MD FRCPC Professor of Medicine – University of Toronto
R Fraser Elliott Chair in Home Dialysis
Director – Division of Nephrology – University Health Network
Bernard Zinman
MDCM, FRCPC, FACP
Director, Leadership Sinai Centre for Diabetes
Sam and Judy Pencer Family Chair in Diabetes
Senior Scientist, Lunenfeld-Tanenbaum Research Institute
Professor of Medicine, University of Toronto
Subodh Verma
MD, PhD, FRCSC, FAHA
Cardiac Surgeon, St. Michael’s Hospital
Professor of Surgery and Pharmacology, University of Toronto
Video Information
- Credit:No Credit Available
- Post Date:November 4, 2016
- Expiry Date:N/A
